Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8IJV

Cryo-EM structure of the gastric proton pump with bound DQ-02

Summary for 8IJV
Entry DOI10.2210/pdb8ijv/pdb
EMDB information35500
DescriptorSodium/potassium-transporting ATPase subunit alpha, Potassium-transporting ATPase subunit beta, 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE, ... (8 entities in total)
Functional Keywordsp-type atpase, p2-type atpase, membrane protein
Biological sourceSus scrofa (pig)
More
Total number of polymer chains2
Total formula weight153170.47
Authors
Abe, K.,Yokoshima, S.,Yoshimori, A. (deposition date: 2023-02-28, release date: 2023-08-30, Last modification date: 2024-10-09)
Primary citationAbe, K.,Ozako, M.,Inukai, M.,Matsuyuki, Y.,Kitayama, S.,Kanai, C.,Nagai, C.,Gopalasingam, C.C.,Gerle, C.,Shigematsu, H.,Umekubo, N.,Yokoshima, S.,Yoshimori, A.
Deep learning driven de novo drug design based on gastric proton pump structures.
Commun Biol, 6:956-956, 2023
Cited by
PubMed Abstract: Existing drugs often suffer in their effectiveness due to detrimental side effects, low binding affinity or pharmacokinetic problems. This may be overcome by the development of distinct compounds. Here, we exploit the rich structural basis of drug-bound gastric proton pump to develop compounds with strong inhibitory potency, employing a combinatorial approach utilizing deep generative models for de novo drug design with organic synthesis and cryo-EM structural analysis. Candidate compounds that satisfy pharmacophores defined in the drug-bound proton pump structures, were designed in silico utilizing our deep generative models, a workflow termed Deep Quartet. Several candidates were synthesized and screened according to their inhibition potencies in vitro, and their binding poses were in turn identified by cryo-EM. Structures reaching up to 2.10 Å resolution allowed us to evaluate and re-design compound structures, heralding the most potent compound in this study, DQ-18 (N-methyl-4-((2-(benzyloxy)-5-chlorobenzyl)oxy)benzylamine), which shows a K value of 47.6 nM. Further high-resolution cryo-EM analysis at 2.08 Å resolution unambiguously determined the DQ-18 binding pose. Our integrated approach offers a framework for structure-based de novo drug development based on the desired pharmacophores within the protein structure.
PubMed: 37726448
DOI: 10.1038/s42003-023-05334-8
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.1 Å)
Structure validation

239492

PDB entries from 2025-07-30

PDB statisticsPDBj update infoContact PDBjnumon